Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
Dual seroreactivity to HIV-1 and HIV-2 in female sex workers in Abidjan, Cote d'Ivoire.
AIDS. 1995 Aug;9(8):955-8. Unique Identifier : AIDSLINE MED/96014972 Ghys PD; Diallo MO; Ettiegne-Traore V; Yeboue KM; Gnaore E; Lorougnon F; Teurquetil MJ; Adom ML; Greenberg AE; Laga M; et al; Projet RETRO-CI, Abidjan, Cote d'Ivoire.
Abstract:
OBJECTIVE: To determine the absolute and proportional prevalence of dual seroreactivity to HIV-1 and HIV-2 in female sex workers in Abidjan, to determine risk determinants for this serologic profile, and to describe the associated clinical and immunological characteristics. DESIGN: Cross-sectional study. SETTING: Confidential clinic for female sex workers in Abidjan. PARTICIPANTS: Female sex workers. MAIN OUTCOME MEASURES: HIV serostatus, CD4+ counts, women with AIDS, behavioural and sociodemographic characteristics. RESULTS: Among 1209 women tested, the overall HIV seroprevalence was 80%, while the prevalence of dual seroreactivity was 30%. Dual seroreactivity accounted for 38% of all HIV infections. Compared with women reacting to HIV-1 only, dually seroreactive women were significantly more likely to have been in sex work for a longer period, to be aged > or = 20 years, and to charge less money for intercourse. No difference in mean CD4+ count was noted between women with dual seroreactivity (561 x 10(6)/l) and HIV-1-seropositive women (558 x 10(6)/l). CONCLUSIONS: Female sex workers in Abidjan had the highest absolute (30%) and proportional rate (38%) of dual seroreactivity yet described in any population. Increased sexual exposure is associated with an increased risk of dual seroreactivity. Although better molecular diagnostic techniques are required, a substantial proportion of female sex workers in Abidjan is likely to be infected with both HIV-1 and HIV-2.
Keywords: Adult Cote d'Ivoire/EPIDEMIOLOGY Cross-Sectional Studies Female Human HIV Infections/*EPIDEMIOLOGY *HIV Seroprevalence *HIV-1 *HIV-2 *Prostitution Risk Factors Support, Non-U.S. Gov't Support, U.S. Gov't, Non-P.H.S. JOURNAL ARTICLE 960228
M9621057
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.